A 45-year-old gentleman presented with nephrotic-range proteinuria (6 g/day) and acute renal impairment. Blood tests revealed active lupus serological markers. He had no other extra-renal lupus manifestations. Renal biopsy showed Class IV lupus nephritis (activity score, 12/24; chronicity score, 1/12; 3 out of 12 glomeruli showed cellular crescents).
Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.
Switching to a dual therapy of dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing on a TAF*-based regimen in maintaining virologic suppression over 96 weeks in virally suppressed adults with HIV-1, according to the long-term data from TANGO presented at the 2020 HIV Glasgow Congress.